What is the recommended dosage and titration schedule for venlafaxine (Effexor) in adults, including starting dose, titration increments, maximum dose, and special considerations for elderly or hepatic impairment?

Venlafaxine (Effexor) Dosing for Depression

Start venlafaxine at 37.5 mg once or twice daily, increase by 75 mg weekly as tolerated, with a typical effective dose of 150-225 mg/day and a maximum of 225 mg/day for most patients. 1

Standard Adult Dosing

Starting Dose

• Begin at 37.5 mg once or twice daily 1
• The extended-release formulation (Effexor XR) can be given once daily, while immediate-release requires twice-daily dosing 2

Titration Schedule

• Increase by 75 mg each week as tolerated 1
• Typically requires 2-4 weeks to reach an efficacious dose of 150-225 mg/day 1
• For treatment-resistant depression, doses can be titrated upward during the first 4 weeks based on clinical response 3

Target and Maximum Doses

• Effective dose range: 150-225 mg/day 1
• Maximum dose: 225 mg/day for outpatient depression 1
• In severe or treatment-resistant depression, doses up to 375 mg/day may be used, particularly in inpatient settings 1, 3, 4
• The FDA label indicates doses up to 225 mg/day for depression, with higher doses studied in clinical trials 2

Duration of Adequate Trial

• Allow 4-6 weeks at target dose to assess response 1

Special Populations

Hepatic Impairment

• Reduce total daily dose by 50% in patients with mild to moderate hepatic impairment 2
• In cirrhosis, venlafaxine clearance decreases by ~50% and elimination half-life increases by ~30% 2
• ODV (active metabolite) clearance decreases by ~30% with elimination half-life prolonged by ~60% 2
• Individual variability is substantial—some patients may require >50% dose reduction 2
• Start at lower doses (e.g., 18.75-37.5 mg daily) and titrate more slowly 2

Renal Impairment

• Reduce total daily dose by 25-50% for GFR 10-70 mL/min 2
• Reduce dose by 50% in patients undergoing hemodialysis 2
• Venlafaxine clearance decreases and elimination half-life increases for both parent drug and ODV in renal impairment 2
• Individualization may be necessary due to high interpatient variability 2

Elderly Patients

• No automatic dose adjustment required based on age alone 2
• However, start at approximately 50% of standard adult dose (e.g., 18.75-37.5 mg daily) and use slower titration 1
• Exercise caution and individualize dosing, particularly when increasing doses 2
• Consider lower starting doses of 50-75 mg daily with gradual increases to 75-225 mg daily 1

Important Clinical Considerations

Formulation Differences

• Extended-release (Effexor XR): Provides once-daily dosing with lower peak concentrations (Cmax ~150 ng/mL for venlafaxine, ~260 ng/mL for ODV) and later time to peak (Tmax 5.5 hours for venlafaxine, 9 hours for ODV) 2
• Immediate-release: Requires twice-daily dosing with higher peaks (Cmax ~225 ng/mL for venlafaxine, ~290 ng/mL for ODV) and earlier peaks (Tmax 2 hours for venlafaxine, 3 hours for ODV) 2
• Both formulations provide equivalent total drug exposure over 24 hours 2

Cardiovascular Monitoring

• Monitor blood pressure, particularly at doses >150 mg/day, as dose-dependent increases in diastolic blood pressure can occur 1, 5
• Cardiac conduction abnormalities have been reported in a small number of patients 1
• Use with caution in patients with cardiac disease 1

Discontinuation

• Taper gradually over 10-14 days when discontinuing to minimize withdrawal symptoms 1, 2
• A withdrawal syndrome has been described with abrupt cessation 1
• Consider tapering in the third trimester of pregnancy after carefully weighing risks and benefits 2

Common Adverse Effects

• Most frequent: nausea (highest in first 2 weeks), headache, insomnia, dry mouth, constipation, sweating, dizziness, somnolence 2, 6
• Sexual dysfunction: abnormal ejaculation, impotence, anorgasmia, decreased libido 2
• Discontinuation rate due to adverse events: 8-18% depending on indication 2

Therapeutic Drug Monitoring

• Therapeutic reference range for active moiety (venlafaxine + ODV): 140-600 ng/mL 7
• Higher concentrations associated with better response in non-responders, but increased risk of adverse effects at supratherapeutic levels 7
• Consider TDM in non-responders to guide dose titration toward higher concentrations within the therapeutic range 7